M&A Deal Summary |
|
|---|---|
| Date | 2025-08-07 |
| Target | Melinta Therapeutics |
| Sector | Life Science |
| Buyer(s) | CorMedix |
| Sellers(s) | Cempra Pharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 300M USD |
SEARCH BY
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company commercially launched its lead product DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is based in Berkeley Heights, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Sector | Life Science |
Development stage biotechnology company focused on infectious disease. It was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-08-09 |
Melinta Therapeutics
Parsippany, New Jersey, United States Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. Melinta Therapeutics is based in New Haven, Connecticut. |
Buy | - |
